Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087871 | 0.79 | DPP4 (0.44) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL1097565 | 0.79 | GAA (0.31) | GAA | |
| SCHEMBL823939 | 0.75 | — | — | |
| SCHEMBL1098144 | 0.74 | CYP2A6 (0.49) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL1108274 | 0.74 | MEN1 (0.39) | GAAMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1099663 | 0.73 | KMO (0.30) | — | |
| SCHEMBL1097452 | 0.72 | DYRK1A (0.36) | MEN1KMT2A | |
| SCHEMBL2977591 | 0.70 | SMN1; SMN2 (0.39) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL2984634 | 0.69 | AKT3 (0.40) | MEN1ALDH1A1MAPTKMT2AL3MBTL1 | |
| SCHEMBL823895 | 0.69 | KMO (0.41) | GAAMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | SOBI, INC. | 2022-08-04 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573964-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-8153632-B2 | Oxygen linked pyrimidine derivatives | S*BIO PTE LTD. (SG) | 2012-04-10 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| WO-2008140420-A2 | PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2008-11-20 | — | — | WO | disclosed |
| EP-1951729-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*Bio Pte Ltd (SG) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007058627-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD (SG) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241291-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | GAA 1551/4885MEN1 4071/4885ALDH1A1 1035/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | GAA 1551/4885MEN1 4071/4885ALDH1A1 1035/4885 |
| US-20170112846-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | GAA 1551/4885MEN1 4071/4885ALDH1A1 1035/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | GAA 1551/4885MEN1 4071/4885ALDH1A1 1035/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | GAA 1551/4885MEN1 4071/4885ALDH1A1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.